GenoMed to U.S. Corporations: We Can Guarantee Lower Healthcare Costs
Thursday September 2, 9:30 am ET
ST. LOUIS, Sept. 2 /PRNewswire-FirstCall/ -- GenoMed, Inc. (Pink Sheets: GMED - News), a Next Generation DM(TM) (Disease Management) company that uses its expertise in genomics to improve clinical outcomes, announced today that it can guarantee lower healthcare costs for large corporations such as General Motors. Yesterday, GM's CEO, Mr. Richard Wagoner, predicted loss of more jobs overseas unless healthcare costs in the United States were reined in.
GenoMed has found a "master" disease gene responsible for as many as 150 common diseases, including most cardiovascular diseases and cancers. The Company has already shown that it can prevent end-stage kidney disease due to diabetes and high blood pressure, which cost Medicare (now CMS) over $18 billion a year. GenoMed has also published superior outcomes in small cases series of patients with psoriasis, emphysema, peripheral vascular disease ("poor circulation"), and West Nile virus encephalitis. GenoMed's approach is expected to yield superior patient outcomes for most of the additional 150 common diseases.
GenoMed can already guarantee lower healthcare costs based on its success with complications of diabetes and hypertension, the two most common adult diseases in America. GenoMed expects to save a large employer 10% in healthcare costs within 12 months, 30% within 3 years, and 50% within 10 years.
Explained Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, "The 'master' disease gene we've found is a gift that keeps on giving. The longer a patient population uses our approach, the more of the 150 common diseases we've found associated with this gene that we'll be able to delay or even prevent altogether. Over the next decade I'm confident that we'll be able to demonstrate that even common cancers can be delayed."
Dr. Moskowitz continued, "By delaying disease, we'll be able to keep employees and retirees out of the hospital, and healthier for longer. This is the best way to lower healthcare costs. Keeping people out of the hospital is what managed care promised to do. But we'll be lowering costs by keeping people healthier, not by restricting their access to needed medical care."
About GenoMed
GenoMed is leading the clinical revolution which medical genomics has already made possible. GenoMed is a Next Generation DM(TM) (Disease Management) company whose mission is to improve clinical outcomes by identifying the genetic pathways that cause disease. GenoMed is currently marketing its protocol for delaying complications like kidney failure due to high blood pressure and diabetes. Eighty million Americans are at increased risk for kidney failure. GenoMed is also marketing its method for delaying emphysema, which 3 million Americans have, and another 60 million smokers are at increased risk of getting.
This summer GenoMed is coordinating nation-wide treatment for West Nile virus using the Company's patent-pending protocol, which exploits already existing, FDA-approved drugs. Anyone can enroll simply by clicking on the "West Nile trial" link at genomed.com .
Safe Harbor Statement
This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) finances and treatments. The words or phrases "ought to," "should," "could," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to: (a) whether our treatment for West Nile virus encephalitis will continue to be as effective as it has been so far in humans; (b) whether our server holds up to increased demand; (c) our research and development being subject to other economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
biz.yahoo.com |
